» Articles » PMID: 22711708

Inhibition of the Kit Ligand/c-Kit Axis Attenuates Metastasis in a Mouse Model Mimicking Local Breast Cancer Relapse After Radiotherapy

Abstract

Purpose: Local breast cancer relapse after breast-saving surgery and radiotherapy is associated with increased risk of distant metastasis formation. The mechanisms involved remain largely elusive. We used the well-characterized 4T1 syngeneic, orthotopic breast cancer model to identify novel mechanisms of postradiation metastasis.

Experimental Design: 4T1 cells were injected in 20 Gy preirradiated mammary tissue to mimic postradiation relapses, or in nonirradiated mammary tissue, as control, of immunocompetent BALB/c mice. Molecular, biochemical, cellular, histologic analyses, adoptive cell transfer, genetic, and pharmacologic interventions were carried out.

Results: Tumors growing in preirradiated mammary tissue had reduced angiogenesis and were more hypoxic, invasive, and metastatic to lung and lymph nodes compared with control tumors. Increased metastasis involved the mobilization of CD11b(+)c-Kit(+)Ly6G(high)Ly6C(low)(Gr1(+)) myeloid cells through the HIF1-dependent expression of Kit ligand (KitL) by hypoxic tumor cells. KitL-mobilized myeloid cells homed to primary tumors and premetastatic lungs, to give rise to CD11b(+)c-Kit(-) cells. Pharmacologic inhibition of HIF1, silencing of KitL expression in tumor cells, and inhibition of c-Kit with an anti-c-Kit-blocking antibody or with a tyrosine kinase inhibitor prevented the mobilization of CD11b(+)c-Kit(+) cells and attenuated metastasis. C-Kit inhibition was also effective in reducing mobilization of CD11b(+)c-Kit(+) cells and inhibiting lung metastasis after irradiation of established tumors.

Conclusions: Our work defines KitL/c-Kit as a previously unidentified axis critically involved in promoting metastasis of 4T1 tumors growing in preirradiated mammary tissue. Pharmacologic inhibition of this axis represents a potential therapeutic strategy to prevent metastasis in breast cancer patients with local relapses after radiotherapy.

Citing Articles

Interleukin-30 subverts prostate cancer-endothelium crosstalk by fostering angiogenesis and activating immunoregulatory and oncogenic signaling pathways.

Ciummo S, Sorrentino C, Fieni C, Di Carlo E J Exp Clin Cancer Res. 2023; 42(1):336.

PMID: 38087324 PMC: 10714661. DOI: 10.1186/s13046-023-02902-y.


Intraoperative radiotherapy in breast cancer: Alterations to the tumor microenvironment and subsequent biological outcomes (Review).

Yang Y, Hou X, Kong S, Zha Z, Huang M, Li C Mol Med Rep. 2023; 28(6).

PMID: 37888611 PMC: 10636769. DOI: 10.3892/mmr.2023.13118.


The roles of small extracellular vesicles in cancer and immune regulation and translational potential in cancer therapy.

Qian K, Fu W, Li T, Zhao J, Lei C, Hu S J Exp Clin Cancer Res. 2022; 41(1):286.

PMID: 36167539 PMC: 9513874. DOI: 10.1186/s13046-022-02492-1.


The impact of intraoperative radiotherapy on breast cancer: focus on the levels of angiogenic factors.

Nafissi N, Mohammadlou M, Akbari M, Mahdavi S, Sheikh M, Borji M World J Surg Oncol. 2022; 20(1):191.

PMID: 35681234 PMC: 9178821. DOI: 10.1186/s12957-022-02653-8.


Identification of genes and pathways leading to metastasis and poor prognosis in melanoma.

Zhang X, Wang W, Wang Y, Jiang G Aging (Albany NY). 2021; 13(18):22474-22489.

PMID: 34582363 PMC: 8507267. DOI: 10.18632/aging.203554.